UB Paderborn / Katalog / Suche / in CDI

Evolution of insulin therapy: past, present, future

Problemy endokrinologii, 2024-01, Vol.69 (6), p.86

2024

Volltextzugriff (PDF)

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation

Annals of oncology, 2009-05, Vol.20 (5), p.921-927

2009

Volltextzugriff (PDF)

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

The lancet oncology, 2013-05, Vol.14 (6), p.490-499

2013

Volltextzugriff (PDF)

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

European journal of cancer (1990), 2004-07, Vol.40 (11), p.1704-1712

2004

Volltextzugriff (PDF)

Epigenetic aging of the demographically non-aging naked mole-rat

Nature communications, 2022-01, Vol.13 (1), p.355-355, Article 355

2022

Volltextzugriff (PDF)

Extrarenal expression of α-klotho, the kidney related longevity gene, in Heterocephalus glaber, the long living Naked Mole Rat

Scientific reports, 2021-07, Vol.11 (1), p.15375-15375, Article 15375

2021

Volltextzugriff (PDF)

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Journal of clinical oncology, 2013-08, Vol.31 (24), p.3004-3011

2013

Volltextzugriff (PDF)

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

Annals of oncology, 2003-09, Vol.14 (9), p.1399-1405

2003

Volltextzugriff (PDF)

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Annals of oncology, 2014-05, Vol.25 (5), p.1044-1052

2014

Volltextzugriff (PDF)

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The New England journal of medicine, 2014-12, Vol.371 (23), p.2167-2177

2014

Volltextzugriff (PDF)

DNA End Joining Becomes Less Efficient and More Error-Prone during Cellular Senescence

Proceedings of the National Academy of Sciences - PNAS, 2004-05, Vol.101 (20), p.7624-7629

2004

Volltextzugriff (PDF)

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study

European journal of cancer (1990), 2013-11, Vol.49 (17), p.3616-3624

2013

Volltextzugriff (PDF)

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

Annals of oncology, 2010-09, Vol.21 (9), p.1810-1816

2010

Volltextzugriff (PDF)

Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1707-1715

2001

Volltextzugriff (PDF)

Factorial Structure and Validity of Depression (PHQ-9) and Anxiety (GAD-7) Scales after Traumatic Brain Injury

Journal of clinical medicine, 2020-03, Vol.9 (3), p.873

2020

Volltextzugriff (PDF)

A human iPSC model of Ligase IV deficiency reveals an important role for NHEJ-mediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors

Cell death and differentiation, 2013-08, Vol.20 (8), p.1089-1100

2013

Volltextzugriff (PDF)

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

Annals of oncology, 2017-09, Vol.28 (9), p.2142-2148

2017

Volltextzugriff (PDF)

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

Annals of oncology, 2004-12, Vol.15 (12), p.1773-1781

2004

Volltextzugriff (PDF)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging

Neuroendocrinology, 2017-01, Vol.105 (3), p.212-244

2017

Volltextzugriff (PDF)

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

The Lancet (British edition), 2010-08, Vol.376 (9742), p.687-697

2010

Volltextzugriff (PDF)

Distinct longevity mechanisms across and within species and their association with aging

Cell, 2023-06, Vol.186 (13), p.2929-2949.e20

2023

Volltextzugriff (PDF)

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Annals of oncology, 2013-01, Vol.24 (1), p.145-152

2013

Volltextzugriff (PDF)

Universal DNA methylation age across mammalian tissues

Nature aging, 2023-09, Vol.3 (9), p.1144

2023

Volltextzugriff (PDF)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

Neuroendocrinology, 2017-01, Vol.105 (3), p.245-254

2017

Volltextzugriff (PDF)

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

Neuroendocrinology, 2017-01, Vol.105 (3), p.310-319

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Evolution of insulin therapy: past, present, future

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

Epigenetic aging of the demographically non-aging naked mole-rat

Extrarenal expression of α-klotho, the kidney related longevity gene, in Heterocephalus glaber, the long living Naked Mole Rat

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

DNA End Joining Becomes Less Efficient and More Error-Prone during Cellular Senescence

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial

Factorial Structure and Validity of Depression (PHQ-9) and Anxiety (GAD-7) Scales after Traumatic Brain Injury

A human iPSC model of Ligase IV deficiency reveals an important role for NHEJ-mediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Distinct longevity mechanisms across and within species and their association with aging

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Universal DNA methylation age across mammalian tissues

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

Suchergebnisse filtern